Progressive supranuclear palsy is a rare condition that affects the brain. The condition is also called Steele-Richardson-Olszewski syndrome. Progressive supranuclear palsy causes the brain cells that ...
People with progressive supranuclear palsy (PSP) who were prescribed benzodiazepine derivatives had a faster decline in PSP Rating Scale (PSPRS) scores than those who didn't have benzodiazepines, a ...
After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
Progressive supranuclear palsy (PSP) is a rare brain disorder that affects approximately 6 in 100,000 people worldwide. It causes muscle weakness and affects gait, balance and overall movement, as ...
Progressive supranuclear palsy (PSP) is a rare, degenerative neurological condition. It usually starts in middle age and can cause symptoms similar to those of Parkinson’s disease. PSP can cause ...
Progressive supranuclear palsy (PSP) is a rare brain disorder. It causes serious and permanent problems with control of gait (walking) and balance. The most obvious sign of the disease is when you can ...
Progressive supranuclear palsy (PSP) is a rare brain disorder that affects approximately 6 in 100,000 people worldwide. It causes muscle weakness and affects gait, balance and overall movement, as ...
Progressive supranuclear palsy (PSP) is a rare neurodegenerative condition that is a form of atypical parkinsonism, meaning that it shares some features with Parkinson's disease. These include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results